Amryt, a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases, today announces a trading update for the nine months ended 30 September 2019.
Amryt, a revenue-generating orphan drug company focused on acquiring, developing and commercialising products that help improve the lives of patients where there is a high unmet medical need, today announces its preliminary unaudited results for the year ended 31 December 2018. It also provides a trading update for Q1 2019.
Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, is pleased to announce positive data from its pharmacokinetic study FM58 of MED2002, the Company’s topical gel for erectile dysfunction.
Amryt, a biopharmaceutical company focused on rare and orphan diseases, is pleased to announce that Lojuxta® (lomitapide) has been approved for funding as an NHS treatment for adult patients with Homozygous Familial Hypercholesterolaemia in England.
Amryt, a biopharmaceutical company focused on rare and orphan diseases, is pleased to announce the signing of four further distribution agreements for Lojuxta® (lomitapide) across the Middle East, where the incidence of Homozygous Familial Hypercholesterolaemia (“HoFH”), the rare cholesterol disorder treated by Lojuxta, is relatively high.
Revenues increased to €12.8m (2016: €1.4m) – driven by growth of Lojuxta drug sales. Cash balances totalled €20.5m at 31 December 2017 (2016: €8.3m), with €10m undrawn from the European Investment Bank facility.
Amryt, a biopharmaceutical company focused on rare and orphan diseases, is pleased to announce that it has further expanded its